Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine (Rescriptor) and nevirapine (Viramune) are described, including drug interactions, trial results, and the potential for resistance.
 ...
PMID:A new class of anti-HIV drugs. 1136 16

The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) for HIV-1 treatment in March. Delavirdine becomes the second non-nucleoside reverse transcriptase inhibitor approved; the first was nevirapine. The drug must be used in antiretroviral combinations because of resistance problems associated with using it alone. Delavirdine's primary side effect is skin rash, occasionally severe enough to cause permanent discontinuation of the treatment. The approval follows weak clinical data; further clinical testing is called for. Cost is relatively low at $2,250 annually.
 ...
PMID:Delavirdine (Rescriptor) approved. 1136 52

The Food and Drug Administration (FDA) has granted accelerated approval for delavirdine (Rescriptor) for use in combination with other anti-HIV drugs. The non-nucleoside reverse transcriptase inhibitor (NNRTI) inhibits the virus through binding with the enzyme and may be synergistic with AZT and ddC. Interim test results have reported viral load reductions with combination therapy. There is no data related to survival or incidence of AIDS-related illnesses. There are few side effects associated with the drug, and its cost is significantly below that of protease inhibitors.
 ...
PMID:Delavirdine gains approval as second NNRTI for anti-HIV combination regimens. 1136 39

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the latest drugs used to treat HIV infection. Three NNRTIs are introduced: Viramune (nevirapine), Rescriptor (delavirdine), and Viracept (nelfinavir). Recommended doses, rates of absorption, side effects, distribution throughout the body, clinical studies, reactions with other drugs, and how the drugs are metabolized are given. A list of agents that may inhibit the effect of Rescriptor and Viracept, such as antihistamines, antibiotics and anti-convulsions, is presented.
 ...
PMID:[New combination medications]. 1136 1

The 1997 HIV/AIDS drugs are outlined and information is provided on their dosage, storage, efficacy, anti-viral effect, effect on T-cells, drug interactions, cross-resistance, cost, and availability. The drugs include Viramune (nevirapine), Rescriptor (delavirdine), and Viracept (nelfinavir).
 ...
PMID:'96-'97 new drugs and the nominees for 1997 are.... 1136 66

Evidence indicates that delavirdine (Rescriptor), when combined with AZT and 3TC, lowers HIV viral load more effectively than either AZT plus 3TC, or AZT plus delavirdine. Greater increases in CD4 counts were not statistically significant. Subjects either were antiretroviral naive or had received fewer than six months of AZT monotherapy.
 ...
PMID:Delavirdine combination and viral load. 1136 93

Recent progress in treatment methods and medicines has made HIV more manageable. Factors contributing to this progress include advances in testing; the use and approval of protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and other nucleosides; and the success of highly active antiretroviral regimens (HAART) and combination therapy. Nucleoside reverse transcriptase inhibitors, such as Zidovudine and Didanosine, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as Nevirapine (Viramune) and Delavirdine (Rescriptor), are recommended for use in combination therapy. The pharmacology, side effects, and contraindications of these types of drugs are provided. Dosages and common side effects are also mentioned.
 ...
PMID:Understanding the reverse transcriptase inhibitors in HIV. 1136 42

The hybrid protocol being followed by AIDS patient Marc Correa is detailed. His regimen, based only on the use of nutritional and immune-based therapies, has reduced his viral load to undetectable levels. Information about ordering his complete current protocol is included. Improvements are also noted for patients who have taken L-methionine for insomnia and Nature?s Biotics soil-based organisms and wild oregano for yeast infections. Some physicians are now putting patients on pharmaceutical regimens with up to six drugs. Even when effective against HIV, these potent combinations can cause side effects leading to organ failure. Keep Hope Alive suggests there may be both benefit and safety in combining drugs like Norvir with Rescriptor or D4T or 3TC, and adding five or six non-toxic, immune-based and nutritional therapies. Contact information is included.
 ...
PMID:Hybrid protocols. 1136 46

Drug options, presented at the 6th Conference on Retroviruses and Opportunistic Infections, for HIV-infected people switching their regimen due to drug failure are examined. Alternatives discussed include use of Zerit after AZT, Epivir versus Rescriptor, and Sustiva versus Viracept. A study of Crixivan and the issue of resistance are also addressed. Results of some studies presented indicate that a switch to a new drug combination should include at least two new drugs, and that Sustiva and Viracept used together with two nukes were better than a Viracept triple combination. Final comments briefly explore the relationship between drug failure and CD4+ T-cell count.
 ...
PMID:For people needing a new drug. 1136 52

It was previously found that certain nonnucleoside reverse transcriptase inhibitors (NNRTI) possess virucidal activity against human immunodeficiency virus type 1 (HIV-1), and it was suggested that the tight-binding mode of inhibition of reverse transcriptase might be important for this virucidal activity (Borkow et al., J. Virol. 71:3023-3030, 1997). To test this, we compared six different NNRTI, including three tight-binding NNRTI, namely UC781, efavirenz (EFV) (Sustiva), and 5-chloro-3-phenylsulfonylindole-2-carboxamide (CSIC), and three rapid-equilibrium NNRTI, delavirdine (DLV) (Rescriptor), nevirapine (NVP) (Viramune), and UC84, in a variety of virucidal tests. Incubation of isolated HIV-1 virions with UC781, EFV, or CSIC rapidly inactivated the virus, whereas DLV, NVP, and UC84 were ineffective in this respect. Exposure of H9+ cells chronically infected by HIV-1 to the tight-binding NNRTI abolished the infectivity of nascent virus subsequently produced by these cells following removal of extracellular drug, thereby preventing cell-to-cell virus transmission in the absence of exogenous drug. In contrast, cell-to-cell transmission of HIV was blocked by DLV, NVP, and UC84 only when the drug remained in the extracellular medium. Pretreatment of uninfected lymphocytoid cells with UC781, EFV, or CSIC, but not DLV, NVP, or UC84, protected these cells from subsequent HIV-1 infection in the absence of extracellular drug. The protective effect was dependent on both the dose of NNRTI and the viral load. The overall virucidal efficacy of the tight-binding NNRTI tested was CSIC > UC781 approximately EFV. We conclude that the tight-binding mode of inhibition is an essential characteristic for virucidal NNRTI and that antiviral potency is an insufficient predictor for virucidal utility of NNRTI.
 ...
PMID:A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. 1201


1